List view / Grid view

Cardiovascular disease

 

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

10 January 2017 | By Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.